The paired box genes are a family of nine developmental control genes, which in human beings (PAX) 
Introduction

The paired box (PAX/Pax) transcription factor family encoded by developmental control genes is characterized by a highly conserved paired-box DNA-binding domain (PD). This domain was initially identified in the Drosophila pair-rule segmentation gene paired (prd). Since that time, PAX/Pax homologues have been discovered in numerous species from nematodes and sea urchins to human beings
. At present, nine paired box genes are known in mice (Pax1 to Pax9) and human beings (PAX1 to PAX9), divided into four subgroups based on two additional motifs, the presence or absence of a conserved octapeptide (OP) [18] . The other member of subgroup I, PAX9, is expressed in normal epithelium of the adult human oesophagus and is absent or significantly reduced in the majority of invasive carcinomas and pre-cancerous epithelial dysplasias [19] .
With regard to subgroup IV, overexpression of PAX4 has been linked to insulinoma and lymphoma. PAX4 is expressed in the early pancreas but later expression is restricted to ␤-cells and is absent in mature islets [20] . PAX4 is highly expressed in human insulinomas [21] . In vitro studies show that PAX4 controls insulinoma cell survival through up-regulation of the anti-apoptotic gene, BCL-XL [22] . Demethylation in the promoter region of PAX4, leading to its overexpression, has been observed in primary lymphoma [23] . The [24] . The overexpression of Pax6 in transgenic mice promotes ductal and islet cell proliferation and the subsequent development of pancreatic cystic adenoma [25] . However, PAX6 exerts a tumour suppressor function that limits the growth of glioblastoma cells. High levels of PAX6 expression are correlated with improved prognosis in malignant astrocytic gliomas, whereas low levels are associated with an unfavourable outcome [26] . PAX6 suppresses the invasiveness of glioblastoma cells by repressing the expression of MMP2 [27] . Methylation and silencing of PAX6 has been observed in breast cancers [28] . Recently, it was reported that Pax6-transduced (non-neuronal) Hela cells express neuron-specific genes and Pax6 expression is a strong signal for induction of cell migration [29] [32, 33] [38] .
. Ectopic expression of Pax3 prevents the myogenic differentiation of myoblasts into myotubes, which might involve the cooperation of Msx1 and Notch genes [34-37]. In chicken embryos, the expression of Msx1 overlaps with Pax3 in migrating limb muscle precursors and Msx1 antagonizes the myogenic activity of Pax3
Msx2, another Msx homeobox gene family member, was found to be an immediate downstream effector of Pax3. Pax3 represses
Msx2 expression in the development of the murine cardiac neural crest [39] . Pax3 potentiates the migration of hypaxial muscle precursors by directly modulating the expression of c-Met tyrosine kinase receptor [40, 41] . Interestingly, in muscle tumours, which often harbour an activated PAX3, c-MET is up-regulated [42] . Therefore, both muscle development and tumourigenesis involve regulation of the MET pathway by PAX3. In P19 carcinoma cells, Wnt3 up-regulates Pax3 expression, which in turn, activates Six1, Eya2 and Dach2. This is followed by the down-regulation of Pax3 and activation of MyoD and myogenin expression [43, 44] [46, 47] . On the other hand, the distinct roles of Pax3 and Pax7 in regenerative myogenesis of adult mammals suggest that Pax3 may not compensate for Pax7 in postnatal muscle development [48] . However, the function of Pax7 in specification of postnatal myogenic satellite cells is still controversial [49, 50] [51, 59] 
. A comparison of the gene expression profiles using microarrays revealed an overexpression of putative PAX3-FKHR target genes, such as DCX, CNR1, in PAX3-FKHR positive ARMS, relative to that in PAX3-FKHR negative ERMS [60]. The role(s) of PAX3/7-FKHR in promoting the different molecular pathogeneses of ARMS and ERMS remains to be tested and would surely prove to be a fruitful topic of study.
PAX3-FKHR can induce cellular transformation and prevent apoptosis [61, 62] . Furthermore, it shows oncogenic effects, predominantly at relatively low levels although suppression of growth occurs at higher levels [59] [67] . The expression of Pax3 is probably necessary, but not sufficient, for maintaining melanocytes in their differentiated state [68] . PAX3 promotes melanocyte lineage commitment while simultaneously preventing their differentiation (Fig. 3) [69] . Furthermore, PAX3 alone or in synergy with SOX10, activates MITF [70] . Failures in this regulation arising from PAX3 mutations cause the auditory-pigmentary symptoms in Waardenburg syndrome 1 patients [71] .
Melanocytes can develop into cutaneous and ocular melanoma. Pigmented ocular tumours can also develop from proliferating cells of the retinal pigment epithelium [72] . The incidence and mortality of cutaneous melanoma have increased at annual rates of 2-3% worldwide over the last 30 years, with the greatest increases seen in elderly men [73] . Melanomas can clinically progress through four subtypes: benign naevi to dysplastic naevi then radial and vertical growth phase melanoma and finally metastatic melanoma (Fig. 3) [74] . Dysplastic naevus has been suggested as the precursor of cutaneous melanoma. [79] . PAX3 is a key transcription factor in regulating the expression of a variety of melanocytic genes [69, 80] .
The transition of melanocytes into clinically characterized melanoma is associated with changes in the function of numerous genes. Melanoma susceptibility genes are CDKN2A and CDK4, those for growth factors, such as bFGF, PDGF and EGF, and for proteins in signalling pathways, especially MAPK, STAT and Nodal [75-78]. Several transcription factors, such as PAX3, MITF, SOX10, c-MYC, PTEN, RAS and c-RET, also play roles in the pathogenesis of melanoma
PAX3 is expressed in primary melanomas and melanoma cell lines but not in the surrounding normal tissues or skin sections. Transfection of melanoma cells with antisense PAX3 oligonucleotides triggers cell death by inducing apoptosis [81, 82]. The down-regulation of Pax3 in interleukin-6 receptor/interleukin-6 induced melanoma cells (B16F10.9) is linked to arrested growth and transdifferentiation to a glial cell phenotype. Pax3 reduction
Fig. 2 A diagrammatic representation summarizing how PAX3 and the chimeric protein, PAX3-FKHR could promote the development of rhabdomyosarcoma (ERMS, embryonal rhabdomyosarcoma and ARMS, alveolar rhabdomyosarcoma).
Fig. 3 The common origin of melanocytes and nerve cells from the neural crest and the development and progression of normal melanocytes to metastatic melanoma. The roles of PAX3 in neurogenesis, melanogenesis and melanoma development are proposed.
also induces a loss of melanogenesis, followed by a sharp decrease in MITF mRNA and gene promoter activity [83] . Recently, PAX3 was identified as a regulator of the melanoma susceptibility and progression genes SCF, TGF-␤, MUC18, RhoC and TIMP3 using microarray analyses [84, 85] . In quiescent cells, the retinoblastoma tumour suppressor protein, pRB, in its unphosphorylated state, interacts with the transcription factor E2F and inhibits the transcription of E2F-responsive genes, which are essential for cell cycle progression. PAX3 interacts strongly with pRB [86] .
PAX3 in neurogenesis and neuroblastoma
Pax3 is expressed in the developing nervous system during early neurogenesis (Fig. 3) [87] . The induction of Pax3 in P19 embryonal carcinoma stem cells is closely linked to subsequent neuronal differentiation [88] . Koblar [90, 91] . [92] . [93] . Abnormally elevated expression of PAX3 has also been found in some neuroblastoma cell lines and tumours [94] .
et al. found that Pax3 regulates the generation of sensory neurons from precursors that originate from the NC [89]. They demonstrated that Pax3 mRNA was initially expressed in all NC cells but was later restricted to neurons. The addition of FGF2 to the cultures significantly increased Pax3 mRNA expression in NC cells and resulted in increased neurogenesis. Neuroblastoma is the commonest extracranial solid tumour in childhood. It is a disease of the sympathicoadrenal lineage of the neural crest, and therefore primary tumours may originate in all sites of peripheral sympathetic ganglia and paraganglia
Many genetic abnormalities have been implicated in neuroblastomas, including amplification of the N-MYC oncogene
Overexpression of transfected N-MYC induces cellular transformation. For example, transgenic mice overexpressing N-MYC in NC-derived tissues frequently develop neuroblastomas. However, a reduced expression of N-MYC in cultured human neuroblastoma cell lines decreases proliferation and induces differentiation
Deletion and mutagenesis experiments have shown that Pax3 contains the inverted E box sequence CGCGTG (or CACGCG) in the 5Ј promoter region, which responds to regulation by N-Myc and c-Myc. Mouse N-Myc and c-Myc directly activate the Pax3 promoter and the ectopic expression of N-Myc and c-Myc increases Pax3 expression [95]. Whether PAX3 initiates pathogenesis of neuroblastoma or N-MYC induces neuroblastoma by modulating PAX3 expression, is a question worthy of further investigation.
PAX3 splicing and tumours
The PAX3 isoforms are designated as PAX3a, PAX3b, PAX3c, PAX3d, PAX3e, PAX3g and PAX3h (Fig. 4) [30, 96, 97] (Fig. 5) . PAX2 RNA interference induces apoptosis in tumour cells [16] . It was demonstrated that inhibition of PAX2 expression in prostate cancer cells results in cell death [103] . Similarly, transfection of antisense PAX2 into Kaposi sarcoma cells results in reduced cell motility, invasiveness and cell death [104] [112] . Moreover, the extent of PAX2 expression is correlated with proliferation index and is significantly higher in patients with metastatic disease.
PAX2 has an anti-apoptotic function in embryonic renal cells [113] . The inhibition of PAX2 expression in RCC cell lines triggers growth inhibition and cell death [111] . An increased in PAX2 expression protects cells against high NaCl concentrationinduced apoptosis [114] . The mechanism of PAX2-mediated protection from cell death is unknown. 
PAX5 in tumourigenesis
The chromosomal rearrangement t(9;14)(p13;q32), which results in the fusion of PAX5 to genes for immunoglobulin heavy chain, has been reported in a subset of non-Hodgkin's lymphomas (NHL) [116] . PAX5 expression occurs in various types of benign and malignant tumours including B-cell NHL, Hodgkin lymphomas, Merkel cell carcinoma, small cell carcinoma, neuroendocrine carcinomas and medulloblastomas [117, 118] . PAX5 is the most frequent site of somatic mutations in acute lymphoblastic leukaemia [119] . Mutations of p53 are associated with astrocytomas and glioblastomas. The expression of PAX5 in astrocytomas is inversely proportional to the expression of p53, and PAX5 can bind to the p53 promoter, repressing its activity [120] [121] . Recently, it was confirmed that PAX5 is expressed in poorly differentiated neuroendocrine tumours but never in well-differentiated classic carcinoid tumours [122] . However, loss of Pax5 in mature B cells can initiate lymphoma development in mice despite their advanced differentiation [123] . This implies that PAX5/Pax5 has cell type specific effects on cell differentiation. PAX5 transcription is enhanced by STAT5 in the early stages of B cell development. Indeed, a STAT-binding motif has been shown to occur in the PAX5 promoter [124] . Constitutive activation of STAT5 is associated strongly with tumourigenesis [125] . The expression of dominant-negative Pax5 in murine lymphomas and PAX5 knockdown in human lymphoma negatively affects cell expansion [126] . Hence PAX5 may contribute to oncogenesis through the STAT signalling pathway and/or by the direct inhibition of p53 expression.
. PAX5 expression is also identified in N-type neuroblastoma cells (a malignant subset), but is absent in S-type cells (a benign subset). The forced expression of PAX5 in S-type cells has been shown to confer N-type characteristics such as increased rate of proliferation and the ability to form colonies in soft agar
PAX8 in tumourigenesis
PAX8 is expressed in most non-invasive urothelial neoplasia but not in normal adult urothelial epithelium [127] . It is highly expressed in epithelial ovarian cancer but expression appears absent in the precursor ovarian surface epithelia of healthy individuals [128] [131] . An in vitro study has shown that PAX8-PPARgamma stimulates thyroid cell viability but inhibits thyroid-specific gene expression [132] . Thus it appears possible that the fusion protein may contribute to the malignant transformation of thyroid follicular cells by modulating the Ras signalling pathway.
PAX and the treatment of cancer
PAX proteins may be useful tools in the diagnosis of cancers. For example, PAX2 immunostaining has been used to identify nephrogenic adenoma [133] . This staining has been recommended as a method to distinguish between metastatic ovarian serous papillary carcinoma and primary breast carcinoma [134] . PAX5 immunohistochemistry is employed in the diagnosis and sub-classification of lymphomas [135] .
Genetic alterations to members of the PAX family directly interfere in transcriptional networks leading to oncogenesis by regulating tumour cell survival, proliferation and migration [16, 22, 23, 65, 81, 114] . Thus some of the PAX genes are potential targets for gene-based cancer therapy. Also, gene-specific therapies, such as antisense oligonucleotides or RNA interferencebased treatments have progressed to clinical trials although these types of treatment have potential problems [136, 137] . However, the in vitro transfection of tumour cells with appropriate PAX gene antisense oligonucleotide or RNA interference molecules induce cell apoptosis or reduce cell proliferation or migration [16, 81, 82, 104, 111, 126] [18, 56, 60, 64, 66, 84, 85, 129] . The vast increases in knowledge of PAX-related activities provided by such studies are being exploited to identify potential new targets for cancer treatment.
